208 related articles for article (PubMed ID: 26050618)
1. Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ; Denessiouk K; Johnson MS; Elenius K
Oncogene; 2016 Mar; 35(10):1283-91. PubMed ID: 26050618
[TBL] [Abstract][Full Text] [Related]
2. Analysis of ERBB4 mutations and expression in japanese patients with lung cancer.
Tomizawa K; Suda K; Onozato R; Kuwano H; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2010 Nov; 5(11):1859-61. PubMed ID: 20975381
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers.
Park SW; Chung NG; Han JY; Eom HS; Yoo NJ; Lee SH
APMIS; 2010 Jan; 118(1):83-4. PubMed ID: 20041876
[No Abstract] [Full Text] [Related]
4. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Tvorogov D; Sundvall M; Kurppa K; Hollmén M; Repo S; Johnson MS; Elenius K
J Biol Chem; 2009 Feb; 284(9):5582-91. PubMed ID: 19098003
[TBL] [Abstract][Full Text] [Related]
5. Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation.
Haryuni RD; Watabe S; Yamaguchi A; Fukushi Y; Tanaka T; Kawasaki Y; Zhou Y; Yokoyama S; Sakurai H
Biochem Biophys Res Commun; 2019 Jun; 514(2):456-461. PubMed ID: 31053301
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
7. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Chakroborty D; Ojala VK; Knittle AM; Drexler J; Tamirat MZ; Ruzicka R; Bosch K; Woertl J; Schmittner S; Elo LL; Johnson MS; Kurppa KJ; Solca F; Elenius K
Cancer Res Commun; 2022 Jan; 2(1):10-27. PubMed ID: 36860695
[TBL] [Abstract][Full Text] [Related]
8. Analysis of regulatory mechanism after ErbB4 gene mutation based on local modeling methodology.
Chen CL; Zhao JW
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323039
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H; Kaplan B; Mertins P; Chen TH; Tanaka KE; Yun CH; Zhang X; Lee SH; Cho J; Ambrogio L; Liao R; Imielinski M; Banerji S; Berger AH; Lawrence MS; Zhang J; Pho NH; Walker SR; Winckler W; Getz G; Frank D; Hahn WC; Eck MJ; Mani DR; Jaffe JD; Carr SA; Wong KK; Meyerson M
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14476-81. PubMed ID: 22908275
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Stephens P; Hunter C; Bignell G; Edkins S; Davies H; Teague J; Stevens C; O'Meara S; Smith R; Parker A; Barthorpe A; Blow M; Brackenbury L; Butler A; Clarke O; Cole J; Dicks E; Dike A; Drozd A; Edwards K; Forbes S; Foster R; Gray K; Greenman C; Halliday K; Hills K; Kosmidou V; Lugg R; Menzies A; Perry J; Petty R; Raine K; Ratford L; Shepherd R; Small A; Stephens Y; Tofts C; Varian J; West S; Widaa S; Yates A; Brasseur F; Cooper CS; Flanagan AM; Knowles M; Leung SY; Louis DN; Looijenga LH; Malkowicz B; Pierotti MA; Teh B; Chenevix-Trench G; Weber BL; Yuen ST; Harris G; Goldstraw P; Nicholson AG; Futreal PA; Wooster R; Stratton MR
Nature; 2004 Sep; 431(7008):525-6. PubMed ID: 15457249
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of the ERBB4 kinase domain in human cancers.
Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Shimamura T; Lowell AM; Engelman JA; Shapiro GI
Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
14. SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase.
Knittle AM; Helkkula M; Johnson MS; Sundvall M; Elenius K
J Biol Chem; 2017 Dec; 292(48):19890-19904. PubMed ID: 28974580
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
17. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
19. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK; von Bubnoff N; Peschel C; Duyster J
Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
